Zoetis Inc

More Details of Zoetis Inc Company

Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).

Company Info

Ticker SymbolZTS

Company nameZoetis Inc

IPO dateFeb 01, 2013

Founded at2012

CEOMs. Kristin C. Peck

Number of employees13800

Security typeOrdinary Share

Fiscal year-endFeb 01

Address10 Sylvan Way

CityPARSIPPANY

Stock exchangeNYSE Consolidated

CountryUnited States of America

Postal code07054

Phone19738227000

Websitehttps://www.zoetis.com/

Ticker SymbolZTS

IPO dateFeb 01, 2013

Founded at2012

Company Executives

Name

Name/Position

Position

Shareholding

Change

Ms. Kristin C. Peck

Chief Executive Officer, Director

95.01K

+0.02%

Mr. Michael B. Mccallister

Non-Executive Independent Chairman of the Board

25.86K

-6.61%

Mr. Gregory (Greg) Norden

Independent Director

16.95K

+12.20%

Ms. Louise M. Parent

Independent Director

15.26K

--

Mr. Frank A. D'amelio

Independent Director

14.81K

--

Mr. Sanjay Khosla

Independent Director

9.81K

--

Mr. Robert J. Polzer, Ph.D.

Executive Vice President, President - Research and Development

6.19K

+0.39%

Ms. Rimma Driscoll

Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices

5.19K

+8.28%

Mr. Jamie Brannan

Executive Vice President, Chief Commercial Officer

2.59K

+19.25%

Mr. Keith Sarbaugh

Executive Vice President, Chief Digital and Technology Officer

2.04K

+94.38%

Name

Name/Position

Position

Shareholding

Change

Ms. Kristin C. Peck

Chief Executive Officer, Director

95.01K

+0.02%

Mr. Michael B. Mccallister

Non-Executive Independent Chairman of the Board

25.86K

-6.61%

Mr. Gregory (Greg) Norden

Independent Director

16.95K

+12.20%

Ms. Louise M. Parent

Independent Director

15.26K

--

Mr. Frank A. D'amelio

Independent Director

14.81K

--

Mr. Sanjay Khosla

Independent Director

9.81K

--

Revenue Breakdown

Currency: USDUpdated: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Parasiticides

2.15B

23.26%

Vaccines

1.83B

19.74%

Dermatology

1.66B

17.88%

Anti-infectives

1.10B

11.88%

Pain and sedation

851.00M

9.19%

Other

1.67B

18.04%

By RegionUSD

Name

Revenue

Proportion

United States

5.07B

54.82%

Other emerging markets

865.00M

9.35%

Other Developed

564.00M

6.09%

Brazil

414.00M

4.47%

Australia

319.00M

3.45%

Other

2.02B

21.82%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Parasiticides

2.15B

23.26%

Vaccines

1.83B

19.74%

Dermatology

1.66B

17.88%

Anti-infectives

1.10B

11.88%

Pain and sedation

851.00M

9.19%

Other

1.67B

18.04%

Shareholding Stats

Updated: Fri, Feb 21

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

9.29%

BlackRock Institutional Trust Company, N.A.

5.20%

State Street Global Advisors (US)

4.45%

State Farm Insurance Companies

3.79%

Geode Capital Management, L.L.C.

2.47%

Other

74.80%

Shareholders

Proportion

The Vanguard Group, Inc.

9.29%

BlackRock Institutional Trust Company, N.A.

5.20%

State Street Global Advisors (US)

4.45%

State Farm Insurance Companies

3.79%

Geode Capital Management, L.L.C.

2.47%

Other

74.80%

Shareholder Types

Shareholders

Proportion

Investment Advisor/Hedge Fund

41.53%

Investment Advisor

38.63%

Research Firm

4.90%

Insurance Company

3.89%

Bank and Trust

2.59%

Pension Fund

2.46%

Sovereign Wealth Fund

1.23%

Hedge Fund

1.20%

Family Office

0.14%

Other

3.43%

Institutional Shareholding

Updated: Sun, Jan 19

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

3223

432.94M

97.24%

-6.88M

2024Q4

3199

430.60M

96.14%

-9.58M

2024Q3

3090

434.14M

95.81%

-13.19M

2024Q2

3062

437.75M

95.94%

-9.33M

2024Q1

3060

439.45M

96.16%

-2.63M

2023Q4

3074

438.13M

95.43%

-2.08M

2023Q3

2966

434.04M

94.28%

-3.00M

2023Q2

2949

430.67M

93.19%

-11.77M

2023Q1

2913

436.42M

94.33%

-5.14M

2022Q4

2889

436.14M

93.57%

-8.47M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

41.17M

9.19%

+127.66K

+0.31%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

22.94M

5.12%

-145.06K

-0.63%

Dec 31, 2024

State Street Global Advisors (US)

19.84M

4.43%

+63.50K

+0.32%

Dec 31, 2024

State Farm Insurance Companies

16.01M

3.58%

-26.09K

-0.16%

Dec 31, 2024

Geode Capital Management, L.L.C.

10.62M

2.37%

+190.14K

+1.82%

Dec 31, 2024

AllianceBernstein L.P.

11.81M

2.64%

-3.58M

-23.26%

Dec 31, 2024

Polen Capital Management, LLC

7.48M

1.67%

+1.12M

+17.54%

Dec 31, 2024

Wellington Management Company, LLP

6.96M

1.55%

+3.06M

+78.46%

Dec 31, 2024

Wells Fargo Advisors

5.67M

1.27%

-330.82K

-5.51%

Dec 31, 2024

BlackRock Asset Management Ireland Limited

4.85M

1.08%

+152.38K

+3.24%

Dec 31, 2024

Related ETFs

Updated: Fri, Jun 6

Name

Proportion

ProShares Pet Care ETF

11.16%

VanEck Agribusiness ETF

8.25%

iShares U.S. Pharmaceuticals ETF

4.87%

Natixis Vaughan Nelson Select ETF

4.13%

VanEck Pharmaceutical ETF

4.03%

SPDR S&P Pharmaceuticals ETF

3.95%

Honeytree US Equity ETF

3.84%

First Trust NASDAQ Pharmaceuticals ETF

3.71%

Jensen Quality Growth ETF

3.52%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

2.54%

ProShares Pet Care ETF

Proportion11.16%

VanEck Agribusiness ETF

Proportion8.25%

iShares U.S. Pharmaceuticals ETF

Proportion4.87%

Natixis Vaughan Nelson Select ETF

Proportion4.13%

VanEck Pharmaceutical ETF

Proportion4.03%

SPDR S&P Pharmaceuticals ETF

Proportion3.95%

Honeytree US Equity ETF

Proportion3.84%

First Trust NASDAQ Pharmaceuticals ETF

Proportion3.71%

Jensen Quality Growth ETF

Proportion3.52%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proportion2.54%

Dividend

A total of 2.94B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Dec 12, 2024

ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Mar 04, 2025 going ex on Jan 21, 2025

Jan 21, 2025

Mar 04, 2025

Jan 21, 2025

Oct 10, 2024

ZTS.NB Final Cash Dividend of gross USD 0.432 paid on Dec 03, 2024 going ex on Oct 31, 2024

Oct 31, 2024

Dec 03, 2024

Oct 31, 2024

May 22, 2024

ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Sep 04, 2024 going ex on Jul 18, 2024

Jul 18, 2024

Sep 04, 2024

Jul 18, 2024

Feb 06, 2024

ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Jun 04, 2024 going ex on Apr 18, 2024

Apr 19, 2024

Jun 04, 2024

Apr 18, 2024

Dec 07, 2023

ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Mar 01, 2024 going ex on Jan 18, 2024

Jan 19, 2024

Mar 01, 2024

Jan 18, 2024

Oct 12, 2023

ZTS.NB Final Cash Dividend of gross USD 0.375 paid on Dec 01, 2023 going ex on Oct 31, 2023

Nov 01, 2023

Dec 01, 2023

Oct 31, 2023

May 11, 2023

ZTS.NB Interim Cash Dividend of gross USD 0.375 paid on Sep 01, 2023 going ex on Jul 20, 2023

Jul 21, 2023

Sep 01, 2023

Jul 20, 2023

Feb 08, 2023

ZTS.NB Interim Cash Dividend of gross USD 0.375 paid on Jun 01, 2023 going ex on Apr 20, 2023

Apr 21, 2023

Jun 01, 2023

Apr 20, 2023

Dec 08, 2022

ZTS.NB Interim Cash Dividend of gross USD 0.375 paid on Mar 01, 2023 going ex on Jan 19, 2023

Jan 20, 2023

Mar 01, 2023

Jan 19, 2023

Oct 13, 2022

ZTS.NB Final Cash Dividend of gross USD 0.325 paid on Dec 01, 2022 going ex on Oct 31, 2022

Nov 01, 2022

Dec 01, 2022

Oct 31, 2022

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

164.330USD

Zoetis Inc

164.330

Overview

Company